Universal Health Coverage: Moving Together, Stronger Together Inside View 07/06/2019 • Editorial team Share this:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to print (Opens in new window) IFPMA event on universal health coverage on the margins of the 72nd World Health Assembly. Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the sidelines of the 72nd World Health Assembly (21-28 May) on why public, private, and civil society partnerships are crucial to attaining universal health coverage. The first-ever United Nations High-Level Meeting (UNHLM) on Universal Health Coverage (UHC), scheduled for 23 September 2019, will soon be upon us. The sense of urgency in preparing for this historic milestone in achieving global health progress was palpable during the World Health Assembly (WHA). There is no lack of often passionate views about what should be included in the UHC political declaration this September in New York. At the IFPMA-hosted WHA side event, “Universal Health Coverage: Moving Together, Stronger Together,” the aim was to dive deeper in a more holistic and probing way and thereby challenge ourselves to find solutions to accelerate progress. We had a high-energy, interactive discussion where different points of view were shared. Here we share with you a few key takeaways from the dynamic discussions. Private sector is a crucial part of the whole for achieving UHC – Everyone has made use of health services or products provided by the private sector; from a doctor or nurse; from medicines or diagnostics; from insurance. One way or another, the private sector is part and parcel of UHC and its involvement is critical in delivering it. Pitting public versus private is an unhelpful discussion. At the WHO Partners Forum this past April, Dr Peter Salama, Executive Director for UHC at the WHO, suggested thinking about PPPs (public-private partnerships) in a new way – as “partnerships for shared outcomes.” This framing encourages all stakeholders to be clearer on the goals, ensure interests are aligned, and that we move together in the same direction. With this spirit in mind, the shared responsibility of public, private, and other stakeholders in making UHC a reality is a sine qua non. Healthcare financing must involve efficiency – Stefan Gijssels, Executive Director of Digestive Cancers Europe & EuropaColon, noted that in Europe the amount of money wasted every year in products and services ($US 300 billion) is more than the entire medicines budget. “It is easy to point the finger at drug pricing but much harder to examine in depth how to be more efficient,” Gijssels concluded. Nelly Wakaba, Country Engagement and Support Director at Financing Alliance for Health, added that one area to explore further for efficiencies is supply chains: in one instance, health care providers were able to drive prices down for the procurement of certain commodities from $18 to $4–$5 by cutting out the middlemen. Susan Henshall, CEO of the Geneva-based City Cancer Challenge agreed, emphasising that there are inefficiencies across the entire health system. Thomas Cueni, Director General of the IFPMA, concluded that when procurement systems are ethical and efficient, significant waste and corruption can be avoided. Data is critical – This was an issue raised by multiple panelists. Henshall emphasised that understanding data helps health ministries to make the right prioritisation decisions. Gijssels noted that cancer survival rates can vary drastically between hospitals in the same city, highlighting how better access to and use of data can inform the right clinical decisions. However, policymakers must also carefully consider who owns and collects the data, pointed out one member of the audience at the side event. No one-size-fits-all approach to UHC – Several comments, including from members of the audience, noted that the source of healthcare financing should be predominantly public, as this is the “only” way to achieve UHC. In his closing remarks, Cueni stressed that decision-makers should be open to various models, tap a wider range of financial resources. Financial innovation should be explored, recognising that some health system models embrace important roles for private insurance, while for some countries, development assistance is still needed. The Final Word – When asked for the three words to explain what they want to see in the UHC political declaration, the answer “put people first” by Henshall and Wakaba got a resounding applause from the audience! About the Authors Githinji Gitahi, CEO, AMREF Health Africa Githinji Gitahi is Group Chief Executive Officer of AMREF Health Africa, the largest Africa-based healthcare nonprofit. The organisation works to strengthen Africa’s health systems and health workers in order to respond to some of the continent’s most pressing challenges in the health space, including maternal and child health, noncommunicable and infectious disease, access to clean water and sanitation, and surgical and clinical outreach. Dr Gitahi is also Co-Chair of the UHC2030 Steering Committee. Prior to his work at AMREF, Dr Gitahi was a Vice President at Smile Train, an NGO that helps children born with cleft lip and palate. He received his Bachelor’s degree in Medicine from the University of Nairobi and his Master’s degree in Business Administration from the US International University. Fumie Griego, Deputy Director General and Chief Operating Officer, IFPMA Fumie Griego is IFPMA’s Deputy Director General and Chief Operating Officer. She joined IFPMA in May 2017 to lead IFPMA’s strategic planning, as well as policy and research for the organisation, with a focus on health policy and economics topics such as value of medicines, government pricing and reimbursement, and metrics/evaluation. Prior to joining IFPMA, Fumie was Head of Global Oncology Policy and Strategy for Global Government Affairs & Policy at Merck KGaA and Vice President for International Health Policy at Pharmaceutical Research and Manufacturers of America (PhRMA). Fumie has worked as a senior economist in the White House’s Office of Management and Budget. She holds a PhD in Health Policy from Harvard University and a Bachelor and Master of Science degrees in Earth Systems (concentration in environmental economics and policy) from Stanford University. Image Credits: IFPMA. Share this:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to print (Opens in new window) Combat the infodemic in health information and support health policy reporting from the global South. Our growing network of journalists in Africa, Asia, Geneva and New York connect the dots between regional realities and the big global debates, with evidence-based, open access news and analysis. To make a personal or organisational contribution click here on PayPal.